Questions about cancer? Freephone 1800 200 700 Irish Cancer Society Nurseline

About this trial

This clinical study compares the efficacy and safety of elacestrant to the standard of care (SoC) options of fulvestrant or an aromatase inhibitor (AI) in women and men with breast cancer whose disease has advanced on at least one endocrine therapy including a CDK4/6 inhibitor in combination with fulvestrant or an aromatase inhibitor (AI).

Patient Profile

Advanced or Metastatic ER+/HER2- Breast Cancer.

Where’s this trial being run?

Bon Secours Cork, Cork University Hospital, Sligo University Hospital, St James’s Hospital, St Vincents University Hospital, University Hospital Limerick, University Hospital Waterford, and Mater Misericordiae University Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.

Summary Data

Name: EMERALD
Number: 19-10 (RAD1901-308)
Full Title:

Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial.

Principal Investigator: Dr Conleth Murphy (Bon Secours Hospital, Cork)
Type: Industry Sponsored
Sponsor:

Radius Pharmaceuticals, Inc.

Recruitment Started: Global: 2018
Ireland: 2019
Global Recruitment Target: 466
Ireland Recruitment Target: